Lung Cancer | Clinical

KEYNOTE-189: Rate of Kidney Toxicity in Patients With NSCLC

November 21, 2021

Nino Balanchivadze, MD, FACP, discuses the rates of acute kidney injury in the KEYNOTE-189 study, which evaluated pembrolizumab and carboplatin/pemetrexed in patients with metastatic non–small cell lung cancer.